S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

GlycoMimetics Stock Forecast, Price & News

+0.11 (+3.70 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $3.08
50-Day Range
MA: $3.79
52-Week Range
Now: $3.08
Volume1.19 million shs
Average Volume884,544 shs
Market Capitalization$147.31 million
P/E RatioN/A
Dividend YieldN/A
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics logo


GlycoMimetics: 4Q Earnings Snapshot
March 2, 2021 |  finance.yahoo.com
Two Immigrants, One Unique Plan For A Biopharma
February 3, 2021 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLYC
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$3.56 per share


Net Income$-57,890,000.00


Market Cap$147.31 million
Next Earnings Date5/7/2021 (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

264th out of 1,972 stocks

Pharmaceutical Preparations Industry

117th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.11 (+3.70 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

Is GlycoMimetics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GlycoMimetics stock.
View analyst ratings for GlycoMimetics
or view top-rated stocks.

What stocks does MarketBeat like better than GlycoMimetics?

Wall Street analysts have given GlycoMimetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GlycoMimetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Friday, May 7th 2021.
View our earnings forecast for GlycoMimetics

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) issued its quarterly earnings results on Monday, March, 1st. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.32).
View GlycoMimetics' earnings history

How has GlycoMimetics' stock price been impacted by Coronavirus?

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLYC stock has increased by 4.8% and is now trading at $3.08.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GLYC?

3 brokers have issued 12-month target prices for GlycoMimetics' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate GlycoMimetics' stock price to reach $15.00 in the next year. This suggests a possible upside of 387.0% from the stock's current price.
View analysts' price targets for GlycoMimetics
or view top-rated stocks among Wall Street analysts.

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the following people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 62, Pay $844.67k)
  • Dr. John L. Magnani, Sr. VP of Research & Chief Scientific Officer (Age 68, Pay $559.45k)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 53, Pay $604.72k)
  • Mr. Brian M. Hahn, Sr. VP & CFO (Age 47)
  • Ms. Stephanie R. Irish, VP of Accounting (Age 50)
  • Mr. Henry Flanner, VP of Technical Operations
  • Mr. Christian Dinneen-Long, VP, Corp. Counsel & Corp. Sec.
  • Mr. Armand Girard, Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. (Age 52)

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.47%), Dimensional Fund Advisors LP (2.53%), Healthcare of Ontario Pension Plan Trust Fund (1.88%), Renaissance Technologies LLC (1.50%), Caas Capital Management LP (1.05%) and Northern Trust Corp (0.90%). Company insiders that own GlycoMimetics stock include Bvf Partners L P/Il and Daniel M Junius.
View institutional ownership trends for GlycoMimetics

Which major investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Caption Management LLC, Federated Hermes Inc., Panagora Asset Management Inc., Northern Trust Corp, Barclays PLC, and LMR Partners LLP.
View insider buying and selling activity for GlycoMimetics
or view top insider-selling stocks.

Which major investors are buying GlycoMimetics stock?

GLYC stock was purchased by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Caas Capital Management LP, Renaissance Technologies LLC, JPMorgan Chase & Co., Russell Investments Group Ltd., HITE Hedge Asset Management LLC, ExodusPoint Capital Management LP, and Wells Fargo & Company MN. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius.
View insider buying and selling activity for GlycoMimetics
or or view top insider-buying stocks.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $3.08.

How much money does GlycoMimetics make?

GlycoMimetics has a market capitalization of $147.31 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does GlycoMimetics have?

GlycoMimetics employs 57 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is www.glycomimetics.com.

Where are GlycoMimetics' headquarters?

GlycoMimetics is headquartered at 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.